https://orcid.org/0000-0002-2622-7233
REFERENCES
- Earp, B. D., Lewis, J., and C. L. Hart. 2021. Racial justice requires ending the war on drugs. The American Journal of Bioethics 21 (4):4–19. doi:10.1080/15265161.2020.1861364.
- Earp, B. D., and J. Savulescu. 2020. Love is the drug: The chemical future of our relationships. In Love is the drug. Manchester: Manchester University Press.
- Fogg, C., T. I. Michaels, S. Salle, Z. W. Jahn, and M. T. Williams. 2021. Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Experimental and Clinical Psychopharmacology 29 (5):539–54. doi:10.1037/pha0000490.
- George, J. R., T. I. Michaels, J. Sevelius, and M. T. Williams. 2020. The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion. Journal of Psychedelic Studies 4 (1):4–15.
- Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30 (12):1181–1197.
- Jacobs, E., A. Murphy-Beiner, I. Roullier, D. Nutt, and M. Spriggs. unpublished. When the trial ends: The ethical and pragmatic case for post-trial provisions in clinical psychedelic research.
- Jacobs, E. unpublished. Transformative experience and informed consent to psychedelic-assisted psychotherapy.
- Johnson, M. W. 2021. Consciousness, religion, and gurus: Pitfalls of psychedelic medicine. ACS Pharmacology & Translational Science 4 (2):578–81. doi:10.1021/acsptsci.0c00198.
- Herzberg, G., K. Conour, J. Butler, A. Emerson, L. S. Gillooly, V. Gold, M. Hayes, L. Mix, and E. Sienknecht. 2019. Towards an ethos of equity and inclusion in the psychedelic movement. Chacruna, December 2019. https://chacruna.net/towards-an-ethos-of-equity-and-inclusion-in-the-psychedelic-movement/
- Jones, G. M. 2023. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. Journal of Psychopharmacology (Oxford, England) 37 (1):61–9. doi:10.1177/02698811221127304.
- Noorani, T. 2021. Containment matters: Set and setting in contemporary psychedelic psychiatry. Philosophy, Psychiatry, & Psychology 28 (3):201–16.
- Noorani, T., A. Garcia-Romeu, T. C. Swift, R. R. Griffiths, and M. W. Johnson. 2018. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology 32 (7):756–69.
- Paul, L. A. 2014. Transformative experience. New York: OUP Oxford.
- Peterson, A., E. A. Largent, H. F. Lynch, J. Karlawish, and D. Sisi. 2023. Journeying to Ixtlan: Ethics of psychedelic medicine and research for alzheimer’s disease and related dementias. AJOB Neuroscience 14 (2):107–123. doi:10.1080/21507740.2022.2148771.
- Smith, W. R., and D. Sisti. 2021. Ethics and ego dissolution: The case of psilocybin. Journal of Medical Ethics 47 (12):807–14.
- Yaden, D. B., B. D. Earp, and R. R. Griffiths. 2022. Ethical issues regarding nonsubjective psychedelics as standard of care. Cambridge Quarterly of Healthcare Ethics: CQ: The International Journal of Healthcare Ethics Committees 31 (4):464–71. doi:10.1017/S096318012200007X.
- Yaden, D. B., and R. R. Griffiths. 2021. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science 4 (2):568–72. doi:10.1021/acsptsci.0c00194.